Key result
Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily reduced the composite risk of cardiovascular death, stroke, and myocardial infarction by 24% (HR 0.76) compared to aspirin alone.
Why the study?
Does rivaroxaban combined with aspirin reduce cardiovascular events in patients with stable ischemic heart disease and peripheral artery disease?
RCT (n=27,395)
Double-blind
1:1:1
Yes
Does rivaroxaban combined with aspirin reduce cardiovascular events in patients with stable ischemic heart disease and peripheral artery disease?
Hazard Ratio: 0.76 (95% CI 0.66–0.86)
Absolute Event Rate: 4.1% vs 5.4%
p-value: p=<0.001
The addition of low-dose rivaroxaban to aspirin significantly reduces major adverse cardiovascular events in patients with stable atherosclerotic vascular disease, albeit with an expected increase in major bleeding.
May support low-dose rivaroxaban plus aspirin in stable vascular disease; leaves open optimal selection and bleeding management in real-world cohorts.
The article considers modern approaches to the secondary prevention of cardiovascular events in patients with stable ischemic heart disease (IHD) and / or atherosclerosis of peripheral arteries (peripheral artery disease - PAD) with the oral anticoagulant rivaroxaban. The results of the first international prospective phase III study COMPASS for the evaluation of efficacy and safety of rivaroxaban including 27 395 patients with stable IHD or PAD, are discussed. The results of the study were presented at European Congress of Cardiology 2017. Rivaroxaban reduced of the risk of cardiovascular death, stroke and myocardial infarction by 24 %. The results of the study confirm the positive balance of risk / benefit and supplement the previously obtained data on the efficacy of rivaroxaban in patients with cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Н. М. Савина (2018) conducted an RCT in Stable ischemic heart disease or peripheral artery disease (n=27,395). Rivaroxaban plus Aspirin vs. Aspirin 100 mg once daily was evaluated on Composite of cardiovascular death, stroke, and myocardial infarction (HR 0.76, 95% CI 0.66-0.86, p=<0.001). Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily reduced the composite risk of cardiovascular death, stroke, and myocardial infarction by 24% (HR 0.76) compared to aspirin alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: